The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update
James A Hendrix, Brad Finger, Michael W Weiner, Giovanni B Frisoni, Takeshi Iwatsubo, Christopher C Rowe, Seong Yoon Kim, Salvador M Guinjoan, Gustavo Sevlever, Maria C Carrillo
Alzheimer's & Dementia | ELSEVIER SCIENCE INC | Published : 2015
The Alzheimer's Disease Neuroimaging Initiative (ADNI), launched in 2004, has worked to accelerate drug development by validating imaging and blood/cerebrospinal fluid biomarkers for Alzheimer's disease clinical treatment trials. ADNI is a naturalistic (nontreatment) multisite longitudinal study. A true public-private partnership, the initiative has set a new standard for data sharing without embargo and for the use of biomarkers in dementia research. The ADNI effort in North America is not the only such effort in the world. The Alzheimer's Association recognized these global efforts and formed Worldwide ADNI (WW-ADNI). By creating a platform for international collaboration and cooperation, ..View full abstract
Awarded by Korea Healthcare technology R&D Project, Ministry of Health and Welfare, Republic of Korea
NA-ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Amorfix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. Pharmacog/E-ADNI is funded by the European Commission and EFPIA in the context of the IMI - Innovative Medicines Initiative funding scheme.J-ADNI-1 and J-ADNI-2 research projects are supported by public funding from the Ministry of Health, Labor and Welfare, and the Ministry of Economy, Trade and Industry (through New Energy and Development Organization), Japan. Industry Scientific Advisory Board of J-ADNI, comprised of 13 pharma companies (Astellas, Bristol Myers-Squibb, Chugai, Daiichi-Sankyo, Dainippon-Sumitomo, Eisai, Eli-Lilly, MSD, Novartis, Pfizer, Shionogi, Takeda, Tanabe-Mitsubishi), contributed funding for J-ADNI-1/2 as a public research.Funding for AIBL has been provided by Australian Government sources - CSIRO, the Science Industry Endowment Fund, NHMRC, the Dementia CRC and the CRC for Mental Health; Commercial sources - Janssen, GE Healthcare, Avid Radiopharmaceuticals, Navidea Biopharmaceuticals; and Alzheimer's Association, The Alzheimer's Drug Discovery Foundation, and an anonymous foundation.Funding for K-ADNI is provided by a grant of the Korea Healthcare technology R&D Project, Ministry of Health and Welfare, Republic of Korea (HI12C0713).Funding for ARG-ADNI is provided by the FLENI foundation, the Perez Companc Foundation and Pan American Energy.